company background image
FIXX

Homology Medicines NasdaqGS:FIXX Stock Report

Last Price

US$1.40

Market Cap

US$80.5m

7D

-9.1%

1Y

-71.9%

Updated

07 Dec, 2022

Data

Company Financials +
FIXX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

FIXX Stock Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.

Homology Medicines, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Homology Medicines
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$5.15
52 Week LowUS$1.30
Beta-0.18
1 Month Change-2.78%
3 Month Change-35.78%
1 Year Change-71.89%
3 Year Change-92.97%
5 Year Changen/a
Change since IPO-92.50%

Recent News & Updates

Recent updates

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Jan 28
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Sep 18
We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Aug 14
Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

May 22
Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Apr 17
Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Mar 13
Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Feb 03
Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Shareholder Returns

FIXXUS BiotechsUS Market
7D-9.1%-0.3%-3.7%
1Y-71.9%-11.2%-21.2%

Return vs Industry: FIXX underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: FIXX underperformed the US Market which returned -20.6% over the past year.

Price Volatility

Is FIXX's price volatile compared to industry and market?
FIXX volatility
FIXX Average Weekly Movement10.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: FIXX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: FIXX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015224Albert Seymourhttps://www.homologymedicines.com

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye.

Homology Medicines, Inc. Fundamentals Summary

How do Homology Medicines's earnings and revenue compare to its market cap?
FIXX fundamental statistics
Market CapUS$80.47m
Earnings (TTM)-US$4.29m
Revenue (TTM)US$3.21m

25.1x

P/S Ratio

-18.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FIXX income statement (TTM)
RevenueUS$3.21m
Cost of RevenueUS$94.85m
Gross Profit-US$91.64m
Other Expenses-US$87.35m
Earnings-US$4.29m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.075
Gross Margin-2,856.61%
Net Profit Margin-133.82%
Debt/Equity Ratio0%

How did FIXX perform over the long term?

See historical performance and comparison